DSKYF DAIICHI SANKYO COMPANY LIMITED
- 33.500
- -0.410-1.21%
DAIICHI SANKYO COMPANY LIMITED News
Double Good News For AstraZeneca's Breast Cancer Drugs
AstraZeneca plc (NASDAQ:AZN) reported topline data from a metastatic breast cancer treatment study.The results showed that Enhertu (trastuzumab deruxtecan) demonstrated a statistically significant and
Daiichi Sankyo And AstraZeneca's Shows Statistically Significant And Clinically Meaningful Improvement In HR+, HER2 Low Breast Cancer: DESTINY-Breast06 Trial Results
Daiichi Sankyo and AstraZeneca's ENHERTU also demonstrated a clinically meaningful progression-free survival improvement in patients with HER2 ultralow expressionPlans for global regulatory submission
Earnings Call Summary | DAIICHI SANKYO COMPANY LIMITED(DSKYF.US) Q4 2023 Earnings Conference
The following is a summary of the Daiichi Sankyo Company, Limited (DSKYF) Q4 2023 Earnings Call Transcript:Financial Performance:Daiichi Sankyo's FY 2023 revenue increased 25.3% year-on-year to ¥1.601
The Nikkei Average in the backstage started with a 297 yen increase, and Daiichi Sankyo and Mitsui E&S are high
[Nikkei Stock Average, TOPIX (table)] Nikkei Average; 37926.06; +297.58TOPIX; 2681.69; +18.16 [Backward Closer Overview] The Nikkei Average in the back was 37926.06 yen, 297.58 yen higher than the previous day, and started by expanding the range of gains from the previous closing (37780.35 yen). Nikkei 225 futures during lunchtime rose in the range of 37740 yen to 38,000 yen. The dollar and yen depreciated by about 40 yen from around 9:00 a.m. to 1 dollar = 156.00-10 yen
Daiichi Sankyo and others announced stock buybacks on 4/25
The stocks that announced share acquisition quota settings on 4/25 (Thursday) are as follows ＜4568＞Daiichi Sankyo 55 million shares (2.9%) 200 billion yen (24/4/26-25/1/15) ＜6702＞Fujitsu 150 million shares (8.2%) 180 billion yen (24/5/1-25/3/31) ＜9531＞East Gas 17 million shares (4.2%) 40 billion yen (24/5/7-25/3/31) ＜430
Vincerx in Selloff After Early-stage Data for Cancer Therapy
AstraZeneca, Daiichi Sankyo Secure Accelerated US FDA Clearance for Cancer Treatment Enhertu
British drugmaker AstraZeneca (AZN.L, AZN.ST) and Japanese partner Daiichi Sankyo scored new regulatory wins for their jointly developed cancer treatment Enhertu in the US, according to a Monday release.
AstraZeneca, Daiichi Sankyo's Solid Tumor Drug Wins US FDA's Accelerated Approval
AstraZeneca (AZN.L, AZN.ST) secured accelerated approval for its antibody drug conjugate Enhertu, co-developed with Daiichi Sankyo (D4S.F), for treating adult patients with unresectable or metastatic HER2-positive solid tumors in the US.
AstraZeneca's Enhertu Granted Approval for HER-2 Positive Tumor-agnostic Indications
FDA Accepts Daiichi Sankyo-AstraZeneca's Breast Cancer Therapy for Review
Pfizer, Gilead, Roche Seen Benefitting the Most From Antibody-drug Conjugates
Daiichi Sankyo-AstraZeneca Gets BLA Approved for Lung Cancer Therapy in the U.S.
DATO-DXD jointly developed by Daiichi Sankyo/AstraZeneca (AZN.US)
On February 19, Daiichi Sankyo/AstraZeneca (AZN.US) jointly announced that its dato-DXD biological product license application (BLA) was accepted by the FDA for use in adult patients with locally advanced or metastatic non-squamous NSCLC who have previously received systemic treatment. The PDUFA date is December 20, 2024.
Datopotamab Deruxtecan Biologics License Application Accepted in the U.S. for Patients With Previously Treated Advanced Nonsquamous Non-Small Cell Lung Cancer
Pharma Giants Turn to China in Search of Targeted Cancer Drugs
Daiichi Sankyo Reports 9M Results
Merck Posts Q4 Beat as Keytruda Outperforms
DAIICHI SANKYO COMPANY LIMITED To Go Ex-Dividend On March 28th, 2024 With 0.264 USD Dividend Per Share
February 1st - $DAIICHI SANKYO COMPANY LIMITED(DSKYF.US)$ is trading ex-dividend on March 28th, 2024. Shareholders of record on March 31st, 2024 will receive 0.264 USD dividend per share on June 2
AstraZeneca Says Enhertu Application for HER2-Positive Solid Tumors Slated for FDA Priority Review
AstraZeneca (AZN) and Daiichi Sankyo said Monday their supplemental biologics license application for Enhertu was granted priority review by the US Food and Drug Administration.
AstraZeneca/ Daiichi Win FDA Priority Review for Enhertu Label Expansion
Accepting the sBLA for priority review, the regulator has issued May 30, 2024, as the Prescription Drug User Fee Act (PDUFA) date for its decision.
Analysis
Price Target
No Data
